問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

Recruiting Trial

1,316Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

3138Cases

2013-08-05 - 2015-11-30

Phase III

A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1, 2, 3 and 6 HCV Infection and in Treatment-Experienced Subjects with Chronic Genotype 2 HCV Infection

  • Condition/Disease

    HCV Infection

  • Test Drug

    Sofosbuvir

Participate Sites
13Sites

Terminated13Sites

2017-07-01 - 2020-03-31

Phase II

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

  • Condition/Disease

    Metastatic Triple Negative Breast Cancer

  • Test Drug

    Olaparib (AZD2281), AZD6738 and AZD1775

Participate Sites
10Sites

Terminated9Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of General Internal Medicine

陳訓徹
Linkou Chang Gung Medical Foundation

2013-09-01 - 2016-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2017-03-17 - 2023-04-17

Phase III

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
4Sites

Recruiting3Sites

2018-10-01 - 2020-09-04

Phase I

A Clinical Trial to Investigate Biomarker Effects of Pre-Surgical Treatment With DDR Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Who Are Planned to Undergo Surgery That is Likely to be Followed by Radiotherapy and/or Chemotherapy.

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Test Drug

    AZD6738, Lynparza

Participate Sites
2Sites

Recruiting2Sites

2018-07-01 - 2021-12-31

Phase III

A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

  • Condition/Disease

    Nasopharyngeal Cancer

  • Test Drug

    JS001

Participate Sites
8Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-03-01 - 2019-09-30

Others

Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer, NSCLC

  • Test Drug

    G1T38

Participate Sites
10Sites

Terminated9Sites

2018-04-25 - 2023-07-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Ustekinumab (STELARA)

Participate Sites
10Sites

Terminated8Sites

張棋楨
Taipei Medical University Hospital

羅淑芬
Linkou Chang Gung Medical Foundation

2020-10-20 - 2022-04-28

Phase III

A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia(ITP)

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2019-12-01 - 2020-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

  • Condition/Disease

    Drug-Resistant Epilepsy/Focal-Onset Seizures

  • Test Drug

    Padsevonil

Participate Sites
8Sites

Terminated8Sites

1 267 268 269 270 271 314
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB